Oramed Pharmaceuticals Inc. (ORMP)

NasdaqCM • Currently down 0.05 (-0.98%) in today's trading session

1 member of Congress has disclosed 1 trade in Oramed Pharmaceuticals Inc. (ORMP) via STOCK Act filings. The most recent disclosure was a sale by Brad Knott on 10 January 2025. Aggregate disclosed activity totals roughly $32.5K in sales (midpoint estimates from bracketed disclosure amounts).

Oramed Pharmaceuticals Inc. is currently trading at $5.05, positioned at 88% of its 52-week range ($2.09 – $5.47).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Portfolio

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$5.05
24h Change
-0.05 (-0.98%)
52 Week Range
$2.09—$5.47
View on NASDAQ

Oramed Pharmaceuticals Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ORMP

Select to highlight on chart
1 transactions
Compliance: 100%
Brad Knott10 Jan 202525 Feb 2025SaleStock$15,001 - $50,000N/A

Select transactions to view their annotations on the chart

No overview data available for this stock

Earnings

Next Report

Q3 2026

12 Nov

EPS Est.

$0.52

Rev. Est.

—

Days Until

76

Recent Quarters

Q2 202610 Aug
EPS$-0.09
Miss 120.9%
Q1 202619 May
EPS$0.91
Q4 202526 Mar
EPS$-0.06
Beat 25.0%
Q3 202513 Nov
EPS$1.13
Beat 2925.0%
Q2 202514 Aug
EPS$-0.05
Miss 25.0%
Q1 202515 May
EPS$-0.19
Miss 533.3%
Q4 202427 Mar
EPS$0.01
Beat 133.3%
Q3 20247 Nov
EPS$-0.48
Miss 9695.9%
Q2 202414 Aug
EPS$0.26
Beat 2500.0%
Q1 20249 May
EPS$0.04
Beat 100.0%
Q4 20236 Mar
EPS$-0.08
Beat 33.3%
Q3 20239 Nov
EPS$-0.08
Beat 11.1%
Q2 202310 Aug
EPS$-0.03
Beat 72.7%
Q1 202311 May
EPS$-0.08
Beat 65.2%
Q4 20226 Mar
EPS$-0.22
Beat 0.0%
Q3 202210 Nov
EPS$-0.18
Beat 30.8%
Q2 202210 Aug
EPS$-0.27
Miss 22.7%
Q1 202212 May
EPS$-0.28
Miss 14.6%
Q4 202111 Jan
EPS$-0.22
Miss 10.0%
Q3 202124 Nov
EPS$-0.21
Miss 110.0%
Q2 202114 Jul
EPS$-0.17
Miss 41.7%
Q1 202113 Apr
EPS$-0.17
Beat 10.5%
Q4 202014 Jan
EPS$-0.23
Miss 43.8%
Q3 202024 Nov
EPS$-0.12
Beat 20.0%
Q2 20207 Jul
EPS$-0.10
Beat 33.3%
Q1 20206 Apr
EPS$-0.21
Beat 16.0%
Q4 20199 Jan
EPS$-0.15
Beat 42.3%
Q3 201927 Nov
EPS$0.13
Beat 138.2%
Q2 201910 Jul
EPS$-0.23
Beat 0.0%
Q1 201910 Apr
EPS$-0.21
Beat 12.5%
Q4 201814 Jan
EPS$-0.25
Miss 31.6%
Q3 201828 Nov
EPS$-0.18
Beat 37.9%
Q2 201812 Jul
EPS$-0.30
Miss 11.1%
Q1 20188 Apr
EPS$-0.20
Beat 35.5%
Q4 201711 Jan
EPS$-0.18
Beat 25.0%
Q3 201729 Nov
EPS$-0.20
Beat 13.0%
Q2 20176 Jul
EPS$-0.15
Beat 44.4%
Q1 20175 Apr
EPS$-0.24
Miss 26.3%
Q4 201611 Jan
EPS$-0.20
Miss 66.7%
Q3 201625 Nov
EPS$-0.37
Miss 105.6%
Q2 20166 Jul
EPS$-0.15
Beat 21.1%
Q1 20166 Apr
EPS$-0.14
Beat 26.3%
Q4 201513 Jan
EPS$-0.21
Miss 10.5%
Q3 201525 Nov
EPS$-0.19
Miss 11.8%
Q2 20151 Jul
EPS$-0.15
Beat 28.6%
Q1 20153 Apr
EPS$-0.15
Beat 31.8%
Q4 20148 Jan
EPS$-0.19
Beat 9.5%
Q3 201414 Nov
EPS$-0.17
Beat 15.0%
Q2 201414 Jul
EPS$-0.18
Miss 20.0%
Q1 201410 Apr
EPS$-0.12
Beat 33.3%
Q4 201314 Jan
EPS$-0.14
Beat 12.5%
Q3 201327 Nov
EPS$-0.10
Q2 201317 Jul
EPS$-0.17
Q1 201311 Apr
EPS$-0.17
Q3 201226 Dec
EPS$-0.14
Q3 201212 Dec
EPS$-0.19
Q2 201212 Jul
EPS$-0.09
Q1 20124 Apr
EPS$-0.17
Q4 201112 Jan
EPS$-0.08
Q3 201129 Nov
EPS$-0.13
Q2 201113 Jul
EPS$0.08
Q1 201112 Apr
EPS$-0.12
Q4 201013 Jan
EPS$-0.12
Q3 201029 Nov
EPS$-0.24
Q2 201014 Jul
EPS$-0.17
Q1 201012 Apr
EPS$-0.08
Q4 200913 Jan
EPS$-0.13
Q3 200925 Nov
EPS$-0.08
Q2 200913 Jul
EPS$-0.11
Q4 200830 Mar
EPS$-0.14
Q4 200813 Jan
EPS$-0.25
Q3 200826 Nov
EPS$-0.27
Q2 200821 Jul
EPS$-0.21
Q1 200814 Apr
EPS$-0.08
Q4 200714 Jan
EPS$-0.09
Q3 200712 Dec
EPS$-0.67
Q2 200723 Jul
EPS$-0.09
Q1 200723 Apr
EPS$-0.10
Q4 200622 Jan
EPS$-0.02
Q3 200614 Dec
EPS$-0.08
Q2 200617 Jul
EPS$-0.05
Q1 200619 May
EPS$-0.00
Q4 20054 Jan
EPS$-0.00
Q3 20054 Nov
EPS$-0.15
Q3 20054 Nov
EPS$-0.00
Q2 200526 Jul
EPS$-0.00
Q2 200512 Jul
EPS$-0.03
Q2 200512 Jul
EPS$-0.03
Q3 20031 Dec
EPS$-0.00
Q3 20031 Dec
EPS$-0.00

Dividends

Dividend History

16 Jan 2026
Amount $0.2500

Stock Splits

Split History

23 Jan 2013Reverse Split
Ratio1:12
14 Jun 2004Stock Split
Ratio33:10

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ORMP

Which members of Congress have traded ORMP?
1 member of Congress has disclosed 1 trade in Oramed Pharmaceuticals Inc. (ORMP) under the STOCK Act: Brad Knott.
When was ORMP most recently disclosed by Congress?
The most recent ORMP disclosure was a sale by Brad Knott on 10 January 2025.
What is the total disclosed congressional trading volume for ORMP?
Members of Congress have disclosed approximately $32.5K in ORMP sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in ORMP?
This ORMP page updates as soon as new STOCK Act disclosures are filed for Oramed Pharmaceuticals Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.